Oxidative stress (OS) increases demyelination during MS, while in vitro it is diminished in response to Omega-3 treatment through the suppression of the pro-inflammatory profile of macrophages (lower IL-6 & TNF-α cytokine secretion) (109). The gene discussed is IL6; the disease is myeloid sarcoma.